Results for:(14 found)
Apr 30, 2014 4:27PM on Top StocksBy StreetAuthority

Robust sales gains, year after year, are hard to achieve -- but not for these companies. Here's why.

Apr 1, 2014 4:36PM on Top StocksBy Benzinga

The market overall is a muddle -- and likely to stay that way. Second quarters are often dicey.

Jul 15, 2013 2:17PM on Top StocksBy MSN Money Partner

Stocks are higher following mixed domestic economic data and better-than-expected quarterly results from another of the nation's biggest banks.

Jun 26, 2013 3:17PM on Top StocksBy Charley Blaine

Stocks surge as fears ease that the Fed will boost interest rates sooner rather than later. Interest rates drop. Gold and silver are battered. Apple falls under $400.

Apr 11, 2013 9:23AM on Top StocksBy Benzinga

Amgen, Celgene and Pharmacyclics see short interest drop recently.

Mar 28, 2013 10:50AM on Top StocksBy Benzinga

There's mixed interest in biotech, biopharmaceutical and emerging pharma companies.

Dec 11, 2012 9:40AM on Top StocksBy TheStockAdvisors

This biotech company's Soliris drug shows promise in treating several rare, life threatening diseases.

Tags: ALXN
Dec 7, 2012 12:31PM on Top StocksBy MSN Money Partner

Roche is upgraded to 'overweight,' while Novartis is downgraded to 'equal weight.'

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More